Effects of cAMP-dependent protein kinase activator and inhibitor on in vivo rolipram binding to phosphodiesterase 4 in conscious rats

Tetsuji Itoh, Koji Abe, Jinsoo Hong, Osamu Inoue, Victor W. Pike, Robert B. Innis, Masahiro Fujita

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Rolipram is a selective inhibitor of phosphodiesterase-4 (PDE4), and positron emission tomography (PET) using [11C]rolipram can monitor the in vivo activity of this enzyme that is part of the cAMP second messenger cascade. cAMP-dependent protein kinase (PKA) phosphorylates PDE4 and increases both enzyme activity and affinity for rolipram. In the present PET study, we examined effects of PKA modulators in conscious rats on the binding of [ 11C](R)-rolipram in comparison to the much less active enantiomer [11C](S)-rolipram. Unilateral injection of a PKA activator (dibutyryl-cAMP) and a PKA inhibitor (Rp-adenosine-3′,5′-cyclic monophosphorothioate) into the striatum significantly increased and decreased, respectively, the binding of [11C](R)-rolipram. These effects were not caused by changes in blood flow or delivery of radioligand to brain, since these agents had no effect on the binding of [11C](S)-rolipram binding. These results support the value of measuring in vivo [ 11C](R)-rolipram binding in brain to assess responses to physiological or pharmacological challenges to the cAMP second messenger system.

Original languageEnglish
Pages (from-to)172-176
Number of pages5
JournalSynapse
Volume64
Issue number2
DOIs
Publication statusPublished - Feb 2010
Externally publishedYes

Fingerprint

Type 4 Cyclic Nucleotide Phosphodiesterase
Rolipram
Protein Kinase Inhibitors
Cyclic AMP-Dependent Protein Kinases
Second Messenger Systems
Positron-Emission Tomography
Phosphodiesterase 4 Inhibitors
Brain
Enzymes
Adenosine
Protein Kinases
Pharmacology
Injections

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Effects of cAMP-dependent protein kinase activator and inhibitor on in vivo rolipram binding to phosphodiesterase 4 in conscious rats. / Itoh, Tetsuji; Abe, Koji; Hong, Jinsoo; Inoue, Osamu; Pike, Victor W.; Innis, Robert B.; Fujita, Masahiro.

In: Synapse, Vol. 64, No. 2, 02.2010, p. 172-176.

Research output: Contribution to journalArticle

Itoh, Tetsuji ; Abe, Koji ; Hong, Jinsoo ; Inoue, Osamu ; Pike, Victor W. ; Innis, Robert B. ; Fujita, Masahiro. / Effects of cAMP-dependent protein kinase activator and inhibitor on in vivo rolipram binding to phosphodiesterase 4 in conscious rats. In: Synapse. 2010 ; Vol. 64, No. 2. pp. 172-176.
@article{45cc5f6abad34e6bb9097d656343f591,
title = "Effects of cAMP-dependent protein kinase activator and inhibitor on in vivo rolipram binding to phosphodiesterase 4 in conscious rats",
abstract = "Rolipram is a selective inhibitor of phosphodiesterase-4 (PDE4), and positron emission tomography (PET) using [11C]rolipram can monitor the in vivo activity of this enzyme that is part of the cAMP second messenger cascade. cAMP-dependent protein kinase (PKA) phosphorylates PDE4 and increases both enzyme activity and affinity for rolipram. In the present PET study, we examined effects of PKA modulators in conscious rats on the binding of [ 11C](R)-rolipram in comparison to the much less active enantiomer [11C](S)-rolipram. Unilateral injection of a PKA activator (dibutyryl-cAMP) and a PKA inhibitor (Rp-adenosine-3′,5′-cyclic monophosphorothioate) into the striatum significantly increased and decreased, respectively, the binding of [11C](R)-rolipram. These effects were not caused by changes in blood flow or delivery of radioligand to brain, since these agents had no effect on the binding of [11C](S)-rolipram binding. These results support the value of measuring in vivo [ 11C](R)-rolipram binding in brain to assess responses to physiological or pharmacological challenges to the cAMP second messenger system.",
author = "Tetsuji Itoh and Koji Abe and Jinsoo Hong and Osamu Inoue and Pike, {Victor W.} and Innis, {Robert B.} and Masahiro Fujita",
year = "2010",
month = "2",
doi = "10.1002/syn.20728",
language = "English",
volume = "64",
pages = "172--176",
journal = "Synapse",
issn = "0887-4476",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Effects of cAMP-dependent protein kinase activator and inhibitor on in vivo rolipram binding to phosphodiesterase 4 in conscious rats

AU - Itoh, Tetsuji

AU - Abe, Koji

AU - Hong, Jinsoo

AU - Inoue, Osamu

AU - Pike, Victor W.

AU - Innis, Robert B.

AU - Fujita, Masahiro

PY - 2010/2

Y1 - 2010/2

N2 - Rolipram is a selective inhibitor of phosphodiesterase-4 (PDE4), and positron emission tomography (PET) using [11C]rolipram can monitor the in vivo activity of this enzyme that is part of the cAMP second messenger cascade. cAMP-dependent protein kinase (PKA) phosphorylates PDE4 and increases both enzyme activity and affinity for rolipram. In the present PET study, we examined effects of PKA modulators in conscious rats on the binding of [ 11C](R)-rolipram in comparison to the much less active enantiomer [11C](S)-rolipram. Unilateral injection of a PKA activator (dibutyryl-cAMP) and a PKA inhibitor (Rp-adenosine-3′,5′-cyclic monophosphorothioate) into the striatum significantly increased and decreased, respectively, the binding of [11C](R)-rolipram. These effects were not caused by changes in blood flow or delivery of radioligand to brain, since these agents had no effect on the binding of [11C](S)-rolipram binding. These results support the value of measuring in vivo [ 11C](R)-rolipram binding in brain to assess responses to physiological or pharmacological challenges to the cAMP second messenger system.

AB - Rolipram is a selective inhibitor of phosphodiesterase-4 (PDE4), and positron emission tomography (PET) using [11C]rolipram can monitor the in vivo activity of this enzyme that is part of the cAMP second messenger cascade. cAMP-dependent protein kinase (PKA) phosphorylates PDE4 and increases both enzyme activity and affinity for rolipram. In the present PET study, we examined effects of PKA modulators in conscious rats on the binding of [ 11C](R)-rolipram in comparison to the much less active enantiomer [11C](S)-rolipram. Unilateral injection of a PKA activator (dibutyryl-cAMP) and a PKA inhibitor (Rp-adenosine-3′,5′-cyclic monophosphorothioate) into the striatum significantly increased and decreased, respectively, the binding of [11C](R)-rolipram. These effects were not caused by changes in blood flow or delivery of radioligand to brain, since these agents had no effect on the binding of [11C](S)-rolipram binding. These results support the value of measuring in vivo [ 11C](R)-rolipram binding in brain to assess responses to physiological or pharmacological challenges to the cAMP second messenger system.

UR - http://www.scopus.com/inward/record.url?scp=72449172000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72449172000&partnerID=8YFLogxK

U2 - 10.1002/syn.20728

DO - 10.1002/syn.20728

M3 - Article

C2 - 19852069

AN - SCOPUS:72449172000

VL - 64

SP - 172

EP - 176

JO - Synapse

JF - Synapse

SN - 0887-4476

IS - 2

ER -